Q32 Bio (QTTB) Income from Continuing Operations (2017 - 2026)
Q32 Bio (QTTB) recorded quarterly Income from Continuing Operations of 7722000.0 in Q1 2026, down 113.38% quarter-over-quarter from 57730000.0 in Q4 2025, and up 30.0% on a YoY basis from 5940124.27 in Q1 2025.
Q32 Bio (QTTB) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Q32 Bio's Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 7722000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 30.0% year-over-year to 7722000.0; the TTM figure through Mar 2026 stood at 33130000.0 (up 156.78% YoY), while the FY2025 annual figure was 29821000.0, up 164.68% from the prior year.
- Income from Continuing Operations was 7722000.0 for Q1 2026 at Q32 Bio, down from 57730000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 92663000.0 in Q1 2022 to a low of 34570000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 4660941.18 across 5 years, with a median of 11031000.0 in 2025.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations surged 8735.88% in 2022, then tumbled 1015.44% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 34570000.0 in 2022, then increased by 21.52% to 27132000.0 in 2023, then soared by 47.7% to 14189000.0 in 2024, then soared by 506.86% to 57730000.0 in 2025, then sank by 113.38% to 7722000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 7722000.0 (Q1 2026), 57730000.0 (Q4 2025), and 7389000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Q32 Bio | 167.59 Mn | 116.84 Mn | - | -7.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.72 Mn |
| Dec 31, 2025 | 57.73 Mn |
| Sep 30, 2025 | -7.39 Mn |
| Jun 30, 2025 | -9.49 Mn |
| Mar 31, 2025 | -11.03 Mn |
| Dec 31, 2024 | -14.19 Mn |
| Sep 30, 2024 | -17.60 Mn |
| Jun 30, 2024 | -15.53 Mn |
| Mar 31, 2024 | 1.21 Mn |
| Dec 31, 2023 | -27.13 Mn |
| Sep 30, 2023 | -13.97 Mn |
| Jun 30, 2023 | -5.81 Mn |
| Mar 31, 2023 | -6.84 Mn |
| Dec 31, 2022 | -34.57 Mn |
| Sep 30, 2022 | -31.64 Mn |
| Jun 30, 2022 | -27.94 Mn |
| Mar 31, 2022 | 92.66 Mn |
| Dec 31, 2021 | -33.58 Mn |
| Sep 30, 2021 | -30.61 Mn |
| Jun 30, 2021 | -30.50 Mn |